Corvus had sold no shares under its $100,000,000 Jefferies program and had suspended it in January. The amendment doubles the ceiling to $200,000,000, with Jefferies paid up to 3.0% of gross proceeds.
Latest Corvus Pharmaceuticals news
We have not published a story on Corvus Pharmaceuticals yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $18.9 million, plus short-term investments of $196.3 million, $215.2 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Corvus Pharmaceuticals
Has Corvus Pharmaceuticals raised money recently?
Our latest story on this, dated Mar 13, 2026: "Corvus Pharmaceuticals raises its at-the-market program to $200,000,000". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Corvus Pharmaceuticals?
Corvus Pharmaceuticals, Inc. trades under the ticker CRVS on NASDAQ.
Where is Corvus Pharmaceuticals listed?
Corvus Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:C17.
What is the SEC CIK of Corvus Pharmaceuticals?
The SEC Central Index Key (CIK) for Corvus Pharmaceuticals, Inc. is 1626971. Its filings are on SEC EDGAR.
How many shares does Corvus Pharmaceuticals have outstanding?
84,120,944 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Corvus Pharmaceuticals listed under?
Our directory records Corvus Pharmaceuticals, Inc. under United States.
What does Corvus Pharmaceuticals do?
Our directory classifies Corvus Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Corvus Pharmaceuticals?
The ISIN recorded for Corvus Pharmaceuticals, Inc. is US2210151005.
Does aibio.space cover Corvus Pharmaceuticals?
aibio.space lists Corvus Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Corvus Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
Is Corvus Pharmaceuticals profitable?
Corvus Pharmaceuticals, Inc. reported a net loss of $15.3 million for the fiscal year ended Dec 31, 2025, and used $32.8 million of cash in operations, per its annual report to the SEC.
How much does Corvus Pharmaceuticals spend on research and development?
$33.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Corvus Pharmaceuticals have?
$215.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Corvus Pharmaceuticals (CRVS) stock news?
Our latest story on Corvus Pharmaceuticals, dated Mar 13, 2026: "Corvus Pharmaceuticals raises its at-the-market program to $200,000,000". Corvus had sold no shares under its $100,000,000 Jefferies program and had suspended it in January. The amendment doubles the ceiling to $200,000,000, with Jefferies paid up to 3.0% of gross proceeds. Source.
What is Corvus Pharmaceuticals's market cap?
We do not publish live share prices. In its annual report, Corvus Pharmaceuticals, Inc. put the market value of shares held by non-affiliates (public float) at $251.9 million as of Jun 30, 2025.
Investor discussion: Corvus Pharmaceuticals
Members talk about Corvus Pharmaceuticals (CRVS). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Corvus Pharmaceuticals, newest first. Each line links the filing it comes from.
Reported a financing. SEC Form 8-K (Items 8.01). Source
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:CRVS on TradingView.
SEC filings and registration
SEC name
Corvus Pharmaceuticals, Inc.
CIK
1626971
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
CRVS (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Phone
(650) 900-4520
Shares outstanding
84,120,944 as of 2026-08-06 (10-Q filed 2026-08-06)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Corvus Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CRVS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio